PER® Congress on Hematologic Malignancies (Winter Hematology®) | Conference

Indirect Comparison Study Shows PFS Superiority for Zanubrutinib vs Acalabrutinib in CLL

March 1st 2024

An indirect comparison study in relapsed/refractory chronic lymphocytic leukemia demonstrated survival benefits with zanubrutinib vs acalabrutinib.

Resistance Mutations Present an Ongoing Challenge in Aggressive Hematologic Malignancies

February 28th 2023

With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.

Wang Details Caveats to Standards of Care for Treating Patients With MCL

February 28th 2023

When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.

New Approvals Continue to Shift Treatment Landscape in Hematologic Malignancies

February 27th 2023

Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.

Progress in Disease Detection Sets the Stage for MRD’s Role in AML

February 27th 2023

For patients with acute myeloid leukemia, advances in targeting minimal residual disease represents the next wave of advances in the field and is necessary to cure this disease.

Davids Highlights Mounting Treatment Options in CLL

February 25th 2023

Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.

Dr. Sauter on Questions Surrounding Novel Therapies in Hematologic Malignancies

February 24th 2023

Craig Sauter, MD, discusses prominent questions surrounding new and emerging therapies in the treatment of patients with hematologic malignancies.

Dr. Wang on Contraindications to Hypomethylating Therapy in Older Patients With AML

February 24th 2023

Eunice Wang, MD, discusses reasons why some older patients with acute myeloid leukemia may not be eligible to receive hypomethylating therapy and highlights ongoing investigations within this older patient population

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

Dr. Cortes on Better Understanding Areas of Interest in ALL

February 24th 2023

Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.

Investigators Push to Leverage Liquid Biopsy As New Standard in Early Detection, Prognosis of Hematologic Malignancies

March 3rd 2022

Leveraging the advances made with liquid biopsies in pantumor assays and specific hematologic cancers has laid the groundwork for the shift in care by using single, or multifaceted approaches for identifying, predicting, and monitoring disease progression.

Targeted Therapies Plus Chemotherapy Provide Path Around Acquired Resistance in AML

February 28th 2022

Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.

Checkpoint Inhibitors and Bispecifics Build Momentum Throughout Lymphoma

February 28th 2022

Although checkpoint inhibitors and bispecific antibodies have come to represent clinical oncology’s fourth leg of treatment—immunotherapy—there remains much to explore within lymphoma.

Treatment and Sequencing Options Continue to Evolve in Relapsed/Refractory DLBCL

February 28th 2022

The emergence of novel agents, including CAR T-cell therapies and antibody-drug conjugates, plus existing options such as chemoimmunotherapy and bone-marrow transplant, have combined to raise questions about the sequencing of these treatments in patients with diffuse large B-cell lymphoma.

Novel Combination Therapies Show Promise in Managing Early Relapse in Multiple Myeloma

March 2nd 2021

There is building evidence that novel combination therapies could be effective in treating early relapsed multiple myeloma.

Genotyping Offers Insights Into Key Characteristics of ALL Subtypes

March 2nd 2021

Genomic sequencing is a critical step in informing the prognosis of patients with acute lymphoblastic leukemia and more information regarding specific subgroups of ALL, such as lineage ambiguous ALL, could pave the way for more personalized therapies for patients.

Armand Reviews Novel Therapeutics in Relapsed/Refractory Follicular Lymphoma

March 2nd 2021

Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

Investigative Interventions Gain Ground in GVHD

March 2nd 2021

With an increased understanding of disease biology, several approaches are under examination to optimize the management of patients with graft-versus-host disease.

New Methods for MRD Testing Help to Predict Relapse Across Multiple Leukemia Subtypes

March 2nd 2021

Minimal residual disease has helped to predict relapse in numerous leukemia subtypes, with novel testing methods helping to identify the biomarker at a higher sensitivity than ever before.

BR Retains its Role in Frontline Waldenström Macroglobulinemia Despite the Utility of BTK Inhibitors

March 1st 2021

The treatment landscape of Waldenström macroglobulinemia is becoming increasingly complex with second-generation BTK inhibitors; however, the combination of bendamustine and rituximab remains the frontline standard of care for this patient population.